Out-of-Specification Sample-Size Confusion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Out-of-Specification Sample-Size Confusion
Precedents set in the historic Barr case continue to raise questions over suitable sample-size criteria.


Pharmaceutical Technology
pp. 28, 54


Lynn D. Torbeck
The sample size needed to investigate an out-of-specification (OOS) result continues to be a point of contention within the pharmaceutical industry. The following quotes from the US vs. Barr Laboratories case, which covered OOS issues, provide good background to the discussion (1):

"... the number of retests performed before a firm concludes that an unexplained out of specification result is invalid or that a product is unacceptable is a matter of scientific judgment."

"Nevertheless, retesting cannot continue ad infinitum. Because such a practice is not scientifically valid ..."

"Such a conclusion cannot be based on 3 of 4 or 5 of 6 passing results, but possibly 7 of 8."

" ... retesting determinations will vary on a case by case basis, a necessary corollary of which is that an inflexible retesting rule, designed to be applied in every circumstance, is inappropriate."

The specific question here is: "How big should the sample be?" and it is the most commonly asked question of a professional statistician. The truth is that there is no simple answer because it depends on the information available. There are at least four possible approaches:

  • Scientific estimate
  • Seven out of eight as in the Barr case
  • Statistical formula with historical estimates
  • Statistical formula with sample.

Scientific estimate

One approach to determine the sample size would be to ask a trained analyst with industry experience to use his or her best scientific judgment to determine what would be an adequate sample size to select. Prior to the Barr case this was (and still is in some places) the standard operating procedure. Although this has scientific basis in the fact that the best person available uses all information to estimate a size, the fact that different people would not get the same number is not scientific. However, the Barr case quotes would seem to support this approach.

Seven out of eight

As in the Barr case, the seven out of eight rule is used by some companies in the absence of any other available information. However, so far there is little statistical justification for seven versus any other value. Some companies choose nine only so they can say they have improved upon the Barr criteria.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here